ALNY Alnylam Inc. Gross Profit Rate

Alnylam Pharmaceuticals (ALNY) demonstrates gross profit margin resilience driven by a diversified drug portfolio that mitigates risks from trial failures. The value remains at 77.30, confirming the effectiveness of its proprietary RNA interference technology for treating rare pathologies. Experienced leadership under Yvonne Greenstreet is successfully transforming the company from a research center into a profitable global business.
Analytical breakdowns and data insights for company Alnylam Pharmaceuticals (ALNY)

Gross margin determines production efficiency by measuring the profit share after deducting direct costs from revenue. Analyzing historical gross margins allows for filtering out market noise and identifying real production shocks. The metric is calculated as the ratio of the difference between revenue and cost of goods sold to total sales. For Alnylam Pharmaceuticals (ALNY), this is critical: the high cost of RNAi development is offset by minimal per-dose production costs and premium pricing power.